The integrin-linked kinase (ILK) is an ankyrin repeat containing serine–threonine protein kinase, which can interact with the cytoplasmic domains of integrin β1 and β3 subunits and can be activated by integrins and growth factors. When overexpressed in epithelial cells, ILK inhibits E-cadherin expression, causing an epithelial to mesenchymal transformation. I demonstrate that ILK represses E-cadherin expression by stimulating the expression of Snail, a transcription factor that binds and represses the E-cadherin promoter. Inhibition of ILK in colon cancer cells with a highly selective ILK inhibitor, or dominant-negative ILK, resulted in the inhibition of Snail expression and a concomitant stimulation of expression of E-cadherin. Inhibition of ILK also suppressed β-catenin/TCF transcriptional activity in APC−/− colon cancer cells and induced cellular growth arrest as well as growth inhibition of human colon tumors xenografted into SCID mice. Inhibition of ILK may reverse the frequent epithelial-to-mesenchymal transformation associated with tumor invasion and metastasis. ILK is a promising target for the control of cancer progression.